 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
DexCom, Inc. (DXCM) focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
The company offers its systems for use by people with diabetes, as well as for use by healthcare providers.
Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators.
On February 13th, Dexcom reported Quarter December 2019 earnings of $1.15 per share on revenue of $462.8 million. The consensus earnings estimate was $0.75 per share on revenue of $457.0 million. Revenue grew 36.9% on a year-over-year basis.
The company said it continues to expect 2020 revenue of $1.725 billion to $1.775 billion. The current consensus estimate is revenue of $1.75 billion for the year ending December 31, 2020.
Shares have sold off along with the rest of the market and are expected to find support at these levels.
Entry Point: $200.00
Stop loss: $193.00
Trading Range: $107.44 to $306.71
Target Price: $220.00
DXCM closed at $243.85.
